DEPARTMENT OF HUMAN SERVICES

Meeting Minutes: Drug Formulary Committee

Date & Time:	May 8, 2019; 5:30-9 PM
Minutes prepared by:	Hind Douiki and Dave Hoang
Location:	Elmer Andersen Building, Room 2370, 540 Cedar Street, St. Paul, MN 55101

Attendance

- Members in attendance: Margaret Artz, R.Ph., Ph.D.; Al Heaton, R.Ph; Kyle Lehenbauer, M.D.; Kathryn Lombardo, M.D.; Stacey Ness, Pharm.D.; Kelly Ruby, Pharm.D.; Michael Sprehe, M.D.; Stuart Williams, J.D.; Mary Mescher Benbenek, APRN, PhD.; Ramona Powell, PharmD.
- Members absent: Monica Brands, RPh.; James Phillips, M.D.
- DHS staff present: Dave Hoang, Pharm.D., MBA
- Others in attendance: Hind Douiki, Pharm.D.; Ariane Casey, Pharm.D.

Report of the Chair

Dr. Ness presided over the meeting.

Approval of Minutes

Minutes from the March 2019 meeting were reviewed and approved.

DHS Housekeeping

- Margaret Artz and Al Heaton re-introduced themselves and briefly shared their work affiliations with the committee.

Old Business

- None

New Business

List of Excluded Drugs Review

- Dave discussed with the committee the Minnesota Statute 256B.0625, subd. 13. This statute involves generic substitutions and DAW codes. Currently, there are no drugs on the list of non-allowable generic substitutions. A motion was made to keep the blank list as is.

New Drugs for Continued PA

- The committee discussed Xofluza and recommended to the department by a unanimous vote that Xofluza remain on PA, with changing "14 years of age or older" to "12 years of age or older" in the last bullet of the Approval Criteria.

New Specialty Drugs for Continued PA

- The committee discussed Lokelma and recommended to the department by a unanimous vote that Lokelma remain on PA, with the following additions to the criteria:
    1. Duration of initial approval is 15 days
    2. Duration of renewal approval is 15 days
- The committee discussed Tibsovo and recommended to the department by a unanimous vote that Tibsovo remain on PA, with the following revisions to the criteria:
    1. The addition of the word "have" in the 4th bullet after "NOT"
    2. In the 5th bullet, add "or dose modification if appropriate" after "to ensure no significant drug interaction exists"
    3. In the 2nd bullet of the renewal criteria, add "as determined by the prescriber" after "no evidence of disease progression"
- The committee discussed Mektovi and recommended to the department by a unanimous vote that Mektovi remain on PA, with the following revisions to the criteria:
    1. Addition of the criterion: "Patient has a diagnosis that is listed in the FDA-approved label"
    2. Changing the 2nd bullet to: "Patient has diagnosis of unresectable locally advanced or metastatic melanoma"
- The committee discussed Braftovi and recommended to the department by a unanimous vote that Braftovi remain on PA, with the following revisions to the criteria:
    1. Addition of the criterion: "Patient has a diagnosis that is listed in the FDA-approved label"
    2. Changing the 2nd bullet to: "Patient has diagnosis of unresectable locally advanced or metastatic melanoma"
- The committee discussed Mulpleta and recommended to the department by a unanimous vote that Mulpleta remain on PA, with the addition of the following criteria:
    1. After the 2nd bullet, add this criterion: "have a platelet count of $< 50 \times 10^9$/L"
    2. Adding this criterion: "Patient is not taking Doptelet"
- The committee discussed Doptelet and recommended to the department by a unanimous vote that Doptelet remain on PA, with the addition of the following criterion: "NOT be scheduled for a thoracotomy, laparotomy, open-heart surgery, craniotomy, or organ resection"
- The committee discussed Ilumya and recommended to the department by a unanimous vote that Ilumya remain on PA and be one of the 3rd tier agents in this class
- The committee discussed Takhzyro and recommended to the department by a unanimous vote that Takhzyro remain on PA.

- The committee discussed Galafold and recommended to the department by a unanimous vote that Galafold remain on PA.
- The committee discussed Vizimpro and recommended to the department by a unanimous vote that Vizimpro remain on PA.
- The committee discussed Talzenna and recommended to the department by a unanimous vote that Talzenna remain on PA, with the following revisions:
    1. Move the 2nd criterion ("be ≥ 18 years old**"**) to become the first criterion
    2. Change the criterion language in the 3rd bullet to the following: "Have HER2-negative or deleterious or suspected-deleterious germline BRCA-mutated breast cancer as detected by an FDA-approved test**"**
- The committee discussed Copiktra and recommended to the department by a unanimous vote that Copiktra remain on PA.
- The committee discussed Arikayce and recommended to the department by a unanimous vote that Arikayce remain on PA
- The committee discussed Lorbrena and recommended to the department by a unanimous vote that Lorbrena remain on PA, with switching the order of the 2nd and 3rd bullets
- The committee discussed Abilify MyCite and recommended to the department by a unanimous vote that Abilify MyCite remain on PA, with the following revisions:
    1. In the 2nd bullet, change the last sub-bullet to the following: "Patient has tolerability to oral aripiprazole with suboptimal effects (as assessed by prescriber) that may be due to adherence problems"
    2. In the 5th bullet, replace "Patient" with "Patient or guardian"
    3. In the 2nd bullet of the Quantity Limits criteria, change "Ability" to "Abilify"

Adjournment

- The meeting was adjourned at approximately 8:33 PM Central Time.